Research programme: immunomodulators - ChemoCentryx
Alternative Names: Chemokine-based immunomodulators - ChemoCentryx; Peptide immunostimulants - ChemoCentryx; ProDendryxLatest Information Update: 01 Dec 2022
At a glance
- Originator ChemoCentryx
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infections
Most Recent Events
- 15 Oct 2003 Preclinical trials in Infections in USA (unspecified route)